Adverse drug reactions (ADRs) are a significant concern in clinical pharmacology, often leading to patient morbidity and increased healthcare costs. This book explores the role of pharmacogenomics in predicting and preventing ADRs by understanding the genetic factors that influence drug metabolism and response. It covers the identification of genetic biomarkers associated with susceptibility to specific ADRs, the development of genetic screening protocols, and the implementation of personalized medicine strategies to mitigate risks. Additionally, the book discusses case studies illustrating how pharmacogenomic insights have successfully reduced the incidence of ADRs in various therapeutic areas. Designed for pharmacologists, geneticists, and healthcare professionals, it provides essential knowledge for enhancing drug safety through genetic-based approaches.
George Nelson specializes in the relationship between pharmacogenomics and adverse drug reactions (ADRs) in dermatology. His research identifies genetic markers that predict the risk of ADRs in patients undergoing dermatological treatments. George has authored numerous studies on preventing and managing ADRs through pharmacogenomic testing and personalized therapy plans. He also offers guidelines for clinicians to utilize pharmacogenomic data to minimize ADRs, ensuring safer and more effective dermatological treatments through personalized medicine.